公开(公告)号：US20040072278A1

公开(公告)日：2004-04-15

申请号：US10405953

申请日：2003-04-01

Applicant: Fluidigm Corporation

Inventor： Hou-Pu Chou ,  Antoine Daridon ,  Kevin Farrell ,  Brian Fowler ,  Yish-Hann Liau ,  Ian D. Manger ,  Hany Ramez Nassef ,  William Throndset

IPC: G01N033/00 ,  C12M001/34 ,  C12Q001/02

CPC classification number: G01N35/00 ,  B01L3/502746 ,  B01L3/502753 ,  B01L3/502761 ,  B01L2200/0636 ,  B01L2200/0647 ,  B01L2200/0652 ,  B01L2200/0668 ,  B01L2200/10 ,  B01L2200/12 ,  B01L2300/0645 ,  B01L2300/0681 ,  B01L2300/0861 ,  B01L2300/0867 ,  B01L2300/087 ,  B01L2300/0887 ,  B01L2300/123 ,  B01L2400/0409 ,  B01L2400/0481 ,  B01L2400/0655 ,  G01N15/1456 ,  G01N15/1468 ,  G01N15/1484 ,  G01N2015/0288 ,  G01N2015/1075 ,  G01N2015/149 ,  G01N2015/1493 ,  Y10T436/11 ,  Y10T436/2575

Abstract: The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and/or detection of particles, such as cells and/or beads. The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and/or analysis of particles, such as cells, viruses, organelles, beads, and/or vesicles. The invention also provides microfluidic mechanisms for carrying out these manipulations and analyses. These mechanisms may enable controlled input, movement/positioning, retention/localization, treatment, measurement, release, and/or output of particles. Furthermore, these mechanisms may be combined in any suitable order and/or employed for any suitable number of times within a system. Accordingly, these combinations may allow particles to be sorted, cultured, mixed, treated, and/or assayed, among others, as single particles, mixed groups of particles, arrays of particles, heterogeneous particle sets, and/or homogeneous particle sets, among others, in series and/or in parallel. In addition, these combinations may enable microfluidic systems to be reused. Furthermore, these combinations may allow the response of particles to treatment to be measured on a shorter time scale than was previously possible. Therefore, systems of the invention may allow a broad range of cell and particle assays, such as drug screens, cell characterizations, research studies, and/or clinical analyses, among others, to be scaled down to microfluidic size. Such scaled-down assays may use less sample and reagent, may be less labor intensive, and/or may be more informative than comparable macrofluidic assays.